EDIT
Price
$2.76
Change
+$0.03 (+1.10%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
228.54M
12 days until earnings call
MCRB
Price
$14.17
Change
+$0.09 (+0.64%)
Updated
Jul 18, 04:04 PM (EDT)
Capitalization
122.95M
18 days until earnings call
Interact to see
Advertisement

EDIT vs MCRB

Header iconEDIT vs MCRB Comparison
Open Charts EDIT vs MCRBBanner chart's image
Editas Medicine
Price$2.76
Change+$0.03 (+1.10%)
Volume$35.38K
Capitalization228.54M
Seres Therapeutics
Price$14.17
Change+$0.09 (+0.64%)
Volume$3.23K
Capitalization122.95M
EDIT vs MCRB Comparison Chart in %
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. MCRB commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and MCRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (EDIT: $2.73 vs. MCRB: $14.08)
Brand notoriety: EDIT and MCRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 75% vs. MCRB: 45%
Market capitalization -- EDIT: $228.54M vs. MCRB: $122.95M
EDIT [@Biotechnology] is valued at $228.54M. MCRB’s [@Biotechnology] market capitalization is $122.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileMCRB’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • MCRB’s FA Score: 1 green, 4 red.
According to our system of comparison, both EDIT and MCRB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while MCRB’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 5 bearish.
  • MCRB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MCRB is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -10.78% price change this week, while MCRB (@Biotechnology) price change was +14.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 10, 2025.

MCRB is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($229M) has a higher market cap than MCRB($123M). EDIT YTD gains are higher at: 114.961 vs. MCRB (-15.283). MCRB has higher annual earnings (EBITDA): -55.82M vs. EDIT (-244.52M). EDIT has more cash in the bank: 221M vs. MCRB (58.8M). EDIT has less debt than MCRB: EDIT (31.1M) vs MCRB (89.5M). EDIT has higher revenues than MCRB: EDIT (35.8M) vs MCRB (0).
EDITMCRBEDIT / MCRB
Capitalization229M123M186%
EBITDA-244.52M-55.82M438%
Gain YTD114.961-15.283-752%
P/E RatioN/AN/A-
Revenue35.8M0-
Total Cash221M58.8M376%
Total Debt31.1M89.5M35%
FUNDAMENTALS RATINGS
EDIT vs MCRB: Fundamental Ratings
EDIT
MCRB
OUTLOOK RATING
1..100
7726
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3636
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
12n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MCRB's Valuation (31) in the Biotechnology industry is in the same range as EDIT (41). This means that MCRB’s stock grew similarly to EDIT’s over the last 12 months.

MCRB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that MCRB’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as MCRB (100). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

EDIT's Price Growth Rating (36) in the Biotechnology industry is in the same range as MCRB (36). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MCRB (100). This means that EDIT’s stock grew similarly to MCRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITMCRB
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EAATF0.02N/A
N/A
Earthworks Industries Inc.
VNRFY10.75N/A
N/A
Vienna Insurance Group
YZCHF1.00N/A
N/A
YANKUANG ENERGY GROUP CO LTD.
KRSOF0.49N/A
N/A
KARSAN OTOMOTIV SANAYII VE TICARET AS
NFPC17.02N/A
N/A
Northfield Precision Instrument Corp.